Patents by Inventor Teruaki Matsui
Teruaki Matsui has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9200008Abstract: A novel heterocyclic compound or a salt thereof useful for selectively inhibiting the degradation of p27Kip1 is provided. The compound or the salt thereof is represented by the following formula (1): wherein A represents an alkyl group, a cycloalkyl group, an aryl group or a heterocyclic group, the group A may have a substituent; the ring B represents a 5- to 8-membered monocyclic heterocyclic ring or a condensed ring containing the monocyclic heterocyclic ring, the ring B may have a substituent; the ring C represents an aromatic ring, the ring C may have a substituent; L represents a linker comprising a main chain having 3 to 5 atoms selected from the group consisting of a carbon atom, a nitrogen atom, an oxygen atom and a sulfur atom, wherein at least one atom in the main chain is a hetero atom selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom, the linker L may have a substituent; and n is 0 or 1.Type: GrantFiled: July 1, 2011Date of Patent: December 1, 2015Assignee: ASKA PHARMACEUTICAL CO., LTD.Inventors: Hiroshi Uchida, Akira Asagarasu, Teruaki Matsui
-
Publication number: 20130079306Abstract: A novel heterocyclic compound or a salt thereof useful for selectively inhibiting the degradation of p27Kip1 is provided. The compound or the salt thereof is represented by the following formula (1): wherein A represents an alkyl group, a cycloalkyl group, an aryl group or a heterocyclic group, the group A may have a substituent; the ring B represents a 5- to 8-membered monocyclic heterocyclic ring or a condensed ring containing the monocyclic heterocyclic ring, the ring B may have a substituent; the ring C represents an aromatic ring, the ring C may have a substituent; L represents a linker comprising a main chain having 3 to 5 atoms selected from the group consisting of a carbon atom, a nitrogen atom, an oxygen atom and a sulfur atom, wherein at least one atom in the main chain is a hetero atom selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom, the linker L may have a substituent; and n is 0 or 1.Type: ApplicationFiled: July 1, 2011Publication date: March 28, 2013Inventors: Hiroshi Uchida, Akira Asagarasu, Teruaki Matsui
-
Patent number: 7799775Abstract: This invention provides pyrimidine derivatives represented by a formula, in the formula, ring A stands for carbocyclic group or heterocyclic group, X1 stands for hydrogen, lower alkyl, amino, etc., X2 stands for hydrogen or lower alkyl, Y stands for a direct bond or sulfur or nitrogen, n stands for an integer of 0-4, and Ar stands for a group of the following formula, or a salt thereof, which concurrently exhibit 5-HT1A agonistic activity and 5-HT3 antagonistic activity and are useful for therapy and treatments of diseases such as IBS. The invention furthermore provides a therapeutic method of IBS, characterized by having 5-HT1A agonistic activity and 5-HT3 antagonistic activity work simultaneously and cooperatively in vivo, which comprises either administering 5-HT3 antagonistic agent which concurrently exhibits 5-HT1A agonistic activity, or administering 5-HT1A agonistic agent and 5-HT3 antagonistic agent simultaneously, in sequence or at an interval.Type: GrantFiled: February 25, 2005Date of Patent: September 21, 2010Assignee: ASKA Pharmaceutical Co., Ltd.Inventors: Michitaka Sato, Teruaki Matsui, Akira Asagarasu, Hiroyuki Hayashi, Sei-ichi Araki, Satoru Tamaoki, Nobuyuki Takahashi, Yukinao Yamauchi, Yoshiko Yamamoto, Norio Yamamoto, Chisato Ogawa
-
Publication number: 20070197551Abstract: This invention provides pyrimidine derivatives represented by a formula, in the formula, ring A stands for carbocyclic group or heterocyclic group, X1 stands for hydrogen, lower alkyl, amino, etc., X2 stands for hydrogen or lower alkyl, Y stands for a direct bond or sulfur or nitrogen, n stands for an integer of 0-4, and Ar stands for a group of the following formula, or a salt thereof, which concurrently exhibit 5-HT1A agonistic activity and 5-HT3 antagonistic activity and are useful for therapy and treatments of diseases such as IBS. The invention furthermore provides a therapeutic method of IBS, characterized by having 5-HT1A agonistic activity and 5-HT3 antagonistic activity work simultaneously and cooperatively in vivo, which comprises either administering 5-HT3 antagonistic agent which concurrently exhibits 5-HT1A agonistic activity, or administering 5-HT1A agonistic agent and 5-HT3 antagonistic agent simultaneously, in sequence or at an interval.Type: ApplicationFiled: February 25, 2005Publication date: August 23, 2007Inventors: Michitaka Sato, Teruaki Matsui, Akira Asagarasu, Hiroyuki Hayashi, Sei-ichi Araki, Satoru Tamaoki, Nobuyuki Takahashi, Yukinao Yamauchi, Yoshiko Yamamoto, Norio Yamamoto, Chisato Ogawa
-
Patent number: 7087624Abstract: Substituted pyrazole compounds represented by formula (I), or salts thereof are disclosed, wherein R1 is —CH(OH)—CH(R4)-(A)n-Y, —CH2—CH(R4)-(A)n-Y, —CO-B1-A-Y or the like (wherein A is a lower alkylene; Y is an aryl group which may be substituted, for example, by halogen, or the like; R4 is a hydrogen atom or a lower alkyl group; B1 is —CH(R4)— or —N(R4)—; and n is 0 or 1); R2 is a hydrogen atom, a lower alkyl group which may be substituted by hydroxyl or the like, or an aralkyl group; R3 is a phenyl group which may be substituted by halogen or the like, or a pyridyl group; and Q is a pyridyl or quinolyl group.Type: GrantFiled: October 27, 2003Date of Patent: August 8, 2006Assignee: Teikoju Hormone Mfg. Co., Ltd.Inventors: Nobuyoshi Minami, Michitaka Sato, Koichi Hasumi, Norio Yamamoto, Katsuyuki Keino, Teruaki Matsui, Arihiro Kanada, Shuji Ohta, Takahisa Saito, Shuichiro Sato, Akira Asagarasu, Satoshi Doi, Motohiro Kobayashi, Jun Sato, Hajime Asano
-
Publication number: 20040087628Abstract: Substituted pyrazole compounds represented by formula (I), or salts thereof are disclosed, wherein R1 is —CH(OH)—CH(R4)-(A)n —Y, —CH2 —CH(R4)-(A)n—Y, —CO—B1-A-Y or the like (wherein A is a lower alkylene; Y is an aryl group which may be substituted, for example, by halogen, or the like; R4 is a hydrogen atom or a lower alkyl group; B1 is —CH(R4)— or —N(R4)—; and n is 0 or 1); R2 is a hydrogen atom, a lower alkyl group which may be substituted by hydroxyl or the like, or an aralkyl group; R3 is a phenyl group which may be substituted by halogen or the like, or a pyridyl group; and Q is a pyridyl or quinolyl group. These substituted pyrazole compounds or their salts have an excellent p38MAP kinase inhibiting effect and are hence useful in the prevention or treatment of tumor necrosis factor &agr;-related diseases, interleukin 1-related diseases, interleukin 6-related diseases or cyclooxygenase II-related diseases.Type: ApplicationFiled: October 27, 2003Publication date: May 6, 2004Inventors: Nobuyoshi Minami, Michitaka Sato, Koichi Hasumi, Norio Yamamoto, Katsuyuki Keino, Teruaki Matsui, Arihiro Kanada, Shuji Ohta, Takahisa Saito, Shuichiro Sato, Akira Asagarasu, Satoshi Doi, Motohiro Kobayashi, Jun Sato, Hajime Asano
-
Patent number: 6667325Abstract: Substituted pyrazole compounds represented by formula (I), or salts thereof are disclosed, wherein R1 is —CH(OH)—CH(R4)—(A)n—Y, —CH2—CH(R4)—(A)n—Y, —CO—B1—A—Y or the like (wherein A is a lower alkylene; Y is an aryl group which may be substituted, for example, by halogen, or the like; R4 is a hydrogen atom or a lower alkyl group; B1 is —CH(R4)— or —N(R4)—; and n is 0 or 1); R2 is a hydrogen atom, a lower alkyl group which may be substituted by hydroxyl or the like, or an aralkyl group; R3 is a phenyl group which may be substituted by halogen or the like, or a pyridyl group; and Q is a pyridyl or quinolyl group. These substituted pyrazole compounds or their salts have an excellent p38MAP kinase inhibiting effect and are hence useful in the prevention or treatment of tumor necrosis factor &agr;-related diseases, interleukin 1-related diseases, interleukin 6-related diseases or cyclooxygenase II-related diseases.Type: GrantFiled: December 3, 2001Date of Patent: December 23, 2003Assignee: Teikoku Hormone Mfg. Co., Ltd.Inventors: Nobuyoshi Minami, Michitaka Sato, Koichi Hasumi, Norio Yamamoto, Katsuyuki Keino, Teruaki Matsui, Arihiro Kanada, Shuji Ohta, Takahisa Saito, Shuichiro Sato, Akira Asagarasu, Satoshi Doi, Motohiro Kobayashi, Jun Sato, Hajime Asano
-
Patent number: 6511997Abstract: Aminopyrazole derivatives represented by formula (I), or salts thereof, wherein X1 and X2 are each a hydrogen atom or a halogen atom, or X1 and X2 may be united together to form a lower alkylenedioxy group, Q is a pyridyl group or a quinolyl group, R1 is a hydrogen atom, a substituted or unsubstituted lower alkyl or aryl group, R2 is a hydrogen atom, a lower alkyl group, or an aralkyl group, and R3 represents a hydrogen atom, an organic sulfonyl group, or —C(═Y)—R4 in which R4 is a hydrogen atom or an organic residue and Y is an oxygen or sulfur atom, provided that, when R3 is a hydrogen atom, R1 is a group other than a hydrogen atom and R2 is a hydrogen atom. These amimopyrazole derivatives or their salts have excellent p38MAP kinase inhibiting activities and are hence useful in the prevention or treatment of diseases associated with tumor necrosis sis factor &agr;, interleukin 1, interleukin 6 or cyclooxygenase II.Type: GrantFiled: June 22, 2001Date of Patent: January 28, 2003Assignee: Teikoku Hormone Mfg. Co., Ltd.Inventors: Nobuyoshi Minami, Michitaka Sato, Koichi Hasumi, Norio Yamamoto, Katsuyuki Keino, Teruaki Matsui, Arihiro Kanada, Shuji Ohta, Takahisa Saito, Shuichiro Sato, Akira Asagarasu, Satoshi Doi, Motohiro Kobayashi, Jun Sato, Hajime Asano
-
Patent number: 5519051Abstract: Compounds are described having the formula ##STR1## wherein A denotes C.dbd.O, CH.sub.2, C.dbd.CH.sub.2 or C.dbd.CH-lower alkyl;B denotes O, NH or N-lower alkyl;X does not exist, or denotes C.dbd.O or CH.sub.2 ;n denotes 2 or 3 when X does not exist, or denotes 1 or 2 when X denotes C.dbd.O or CH.sub.2 ; andthe broken line between the 1- and 2-positions of the steroid skeleton means that a double bond may optionally exist there. These compounds have an aromatase inhibition action and are useful for prophylaxis or treatment of diseases caused by excess of estrogens, for example, breast cancer, uterine cancer, prostatic hypertrophy, etc.Type: GrantFiled: September 28, 1993Date of Patent: May 21, 1996Assignee: Teikoku Hormone Mfg. Co., Ltd.Inventors: Naoyuki Koizumi, Shigehiro Takegawa, Shigeki Iwashita, Tomoko Kawachi, Teruaki Matsui, Seijiro Honma, Hiroo Takahashi, Mamoru Mieda, Koichi Minato, Kenyu Shibata, Mitsuteru Numazawa
-
Patent number: 5472962Abstract: A benzothiophene derivative represented by the formula ##STR1## or a salt thereof has an excellent antiestrogenic activity, and is useful as a therapeutic agent of breast cancer, endometrial cancer, endometriosis, mastopathy, etc.This compound is characterized in that the 2-position (the substituent R.sup.2) of the benzothiophene nucleus is substituted by a halogen atom; a lower alkyl group; or a cycloalkyl or cycloalkenyl group optionally substituted by a lower alkyl group, a hydroxyl group, acyloxy group or an oxo group.Type: GrantFiled: May 13, 1994Date of Patent: December 5, 1995Assignee: Teikoku Hormone Mfg. Co., Ltd.Inventors: Naoyuki Koizumi, Shigehiro Takegawa, Shigeki Iwashita, Tomoko Kawachi, Teruaki Matsui, Mamoru Mieda, Hiroo Takahashi, Tomoyuki Saito, Kenyu Shibata